10:55 AM Here's the daily dose of Afrezza predictions and commentary: Like Summer Street and Brinson Patrick, Piper likes the inhaled insulin product's chances for FDA approval and ups the price target on MannKind (MNKD +1%) to $8.40 from $6. There could be "lucrative licensing agreements" in the company's future if all goes according to plan, analyst Ian Somaiya says. Some of the names tossed about: Bristol-Myers, AstraZeneca, Novo Nordisk, Eli Lilly, and Sanofi. Read comments

OOG